A rosszindulatú daganatok gyógyszeres terápiájának irányelvei: A malignus progresszió szerepe a hatóanyagok kiválasztásában.

Translated title of the contribution: Principles of drug therapy of malignant tumors: the role of malignant progression in the choice of effective drugs

A. Jeney, A. Rosta

Research output: Contribution to journalArticle

Abstract

The progress that has been achieved in the development of antitumour drugs and the management of the untoward side effects both contributed to the increasing importance of drug-therapy beside surgery and radiotherapy in cancer treatment. The treatment of the micrometastasis which appears very frequently already at the time of the diagnosis and also the control of the metastatic progression represent the main importance of drug therapy in cancer patients. In spite of the numerous clinical trials indicating the usefulness of drug therapy both as adjuvant in the management of the primary tumours and in the treatment of metastatic tumours there are certain reservation against chemotherapy in medical circle. It is noteworthy that at the present time the strategy of cancer-therapy is subject of considerate changes. Beside to achieve cure by eradication of the tumour cells it has been recommended in various oncological center that stabilization of the malignant disease and to offer a good quality of life for the patients should also be the aim of the therapy. The purpose of this communication is to present those factors which are necessary to consider in the planning of anticancer drug therapy. Certainly to achieve cure or to improve the quality of life of cancer patients it is important to select the most appropriate drug (cytostatics, hormones, biological response modifiers or agents improving the quality of life) and treatment schedule. Since antitumour drug therapy must be classified as active, palliative/active, palliative and supportive/terminal treatments the present survey gives emphases on the underlying role of malignant progression before deciding the type of treatment.

Original languageHungarian
Pages (from-to)1245-1249
Number of pages5
JournalOrvosi Hetilap
Volume140
Issue number22
Publication statusPublished - May 30 1999

Fingerprint

Drug Therapy
Pharmaceutical Preparations
Neoplasms
Quality of Life
Therapeutics
Antineoplastic Agents
Neoplasm Micrometastasis
Immunologic Factors
Cytostatic Agents
Appointments and Schedules
Radiotherapy
Clinical Trials
Hormones

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A rosszindulatú daganatok gyógyszeres terápiájának irányelvei : A malignus progresszió szerepe a hatóanyagok kiválasztásában. / Jeney, A.; Rosta, A.

In: Orvosi Hetilap, Vol. 140, No. 22, 30.05.1999, p. 1245-1249.

Research output: Contribution to journalArticle

@article{1a10640da8cd4624bb47d9233b7dd7d9,
title = "A rosszindulat{\'u} daganatok gy{\'o}gyszeres ter{\'a}pi{\'a}j{\'a}nak ir{\'a}nyelvei: A malignus progresszi{\'o} szerepe a hat{\'o}anyagok kiv{\'a}laszt{\'a}s{\'a}ban.",
abstract = "The progress that has been achieved in the development of antitumour drugs and the management of the untoward side effects both contributed to the increasing importance of drug-therapy beside surgery and radiotherapy in cancer treatment. The treatment of the micrometastasis which appears very frequently already at the time of the diagnosis and also the control of the metastatic progression represent the main importance of drug therapy in cancer patients. In spite of the numerous clinical trials indicating the usefulness of drug therapy both as adjuvant in the management of the primary tumours and in the treatment of metastatic tumours there are certain reservation against chemotherapy in medical circle. It is noteworthy that at the present time the strategy of cancer-therapy is subject of considerate changes. Beside to achieve cure by eradication of the tumour cells it has been recommended in various oncological center that stabilization of the malignant disease and to offer a good quality of life for the patients should also be the aim of the therapy. The purpose of this communication is to present those factors which are necessary to consider in the planning of anticancer drug therapy. Certainly to achieve cure or to improve the quality of life of cancer patients it is important to select the most appropriate drug (cytostatics, hormones, biological response modifiers or agents improving the quality of life) and treatment schedule. Since antitumour drug therapy must be classified as active, palliative/active, palliative and supportive/terminal treatments the present survey gives emphases on the underlying role of malignant progression before deciding the type of treatment.",
author = "A. Jeney and A. Rosta",
year = "1999",
month = "5",
day = "30",
language = "Hungarian",
volume = "140",
pages = "1245--1249",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "22",

}

TY - JOUR

T1 - A rosszindulatú daganatok gyógyszeres terápiájának irányelvei

T2 - A malignus progresszió szerepe a hatóanyagok kiválasztásában.

AU - Jeney, A.

AU - Rosta, A.

PY - 1999/5/30

Y1 - 1999/5/30

N2 - The progress that has been achieved in the development of antitumour drugs and the management of the untoward side effects both contributed to the increasing importance of drug-therapy beside surgery and radiotherapy in cancer treatment. The treatment of the micrometastasis which appears very frequently already at the time of the diagnosis and also the control of the metastatic progression represent the main importance of drug therapy in cancer patients. In spite of the numerous clinical trials indicating the usefulness of drug therapy both as adjuvant in the management of the primary tumours and in the treatment of metastatic tumours there are certain reservation against chemotherapy in medical circle. It is noteworthy that at the present time the strategy of cancer-therapy is subject of considerate changes. Beside to achieve cure by eradication of the tumour cells it has been recommended in various oncological center that stabilization of the malignant disease and to offer a good quality of life for the patients should also be the aim of the therapy. The purpose of this communication is to present those factors which are necessary to consider in the planning of anticancer drug therapy. Certainly to achieve cure or to improve the quality of life of cancer patients it is important to select the most appropriate drug (cytostatics, hormones, biological response modifiers or agents improving the quality of life) and treatment schedule. Since antitumour drug therapy must be classified as active, palliative/active, palliative and supportive/terminal treatments the present survey gives emphases on the underlying role of malignant progression before deciding the type of treatment.

AB - The progress that has been achieved in the development of antitumour drugs and the management of the untoward side effects both contributed to the increasing importance of drug-therapy beside surgery and radiotherapy in cancer treatment. The treatment of the micrometastasis which appears very frequently already at the time of the diagnosis and also the control of the metastatic progression represent the main importance of drug therapy in cancer patients. In spite of the numerous clinical trials indicating the usefulness of drug therapy both as adjuvant in the management of the primary tumours and in the treatment of metastatic tumours there are certain reservation against chemotherapy in medical circle. It is noteworthy that at the present time the strategy of cancer-therapy is subject of considerate changes. Beside to achieve cure by eradication of the tumour cells it has been recommended in various oncological center that stabilization of the malignant disease and to offer a good quality of life for the patients should also be the aim of the therapy. The purpose of this communication is to present those factors which are necessary to consider in the planning of anticancer drug therapy. Certainly to achieve cure or to improve the quality of life of cancer patients it is important to select the most appropriate drug (cytostatics, hormones, biological response modifiers or agents improving the quality of life) and treatment schedule. Since antitumour drug therapy must be classified as active, palliative/active, palliative and supportive/terminal treatments the present survey gives emphases on the underlying role of malignant progression before deciding the type of treatment.

UR - http://www.scopus.com/inward/record.url?scp=0033617622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033617622&partnerID=8YFLogxK

M3 - Article

C2 - 10377736

AN - SCOPUS:0033617622

VL - 140

SP - 1245

EP - 1249

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 22

ER -